Project Search

Building upon their established single-cell microfluidic methods and capabilities to enable the rapid, high-throughput selection of monoclonal antibodies (mAbs) for therapeutic and research applications, researchers aimed to further develop and validate the technology for commercialization.

The new technology and process established by this project increased the throughput required to find rare high-affinity antibodies, provided robust amplification of variable region genes from single cells; demonstrated capabilities in selecting fully human mAbs and dramatically improved speed and cost compared to alternative methods.

These tools will be applied to the rapid selection and sequencing of new human monoclonal antibodies specific to different strains of influenza virus, followed by cloning and expression to confirm the desired antibody binding properties have been obtained.

The success of these activities demonstrated the critical proof-of-concept needed to raise funds and establish the new BC start-up company, AbCellera Biologics Inc, which became revenue generating in 2015.